Mobilan is a nanoparticle-formulated, recombinant non-replicating adenovirus in preclinical development as a universal cancer therapy.

In preclinical studies, delivery of Mobilan to tumor cells caused constant toll-like receptor 5 (TLR5) signaling that induced innate immune response to the tumor with subsequent development of adaptive immune response.

Panacela, our joint venture, holds worldwide development and commercialization rights to Mobilan.

You are now leaving this website. If you would like to continue, click Continue.